Relevance of mitochondrial genetics and metabolism in cancer development

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 2, 2013, Pages

  Gasparre, Giuseppe ^a   Porcelli, Anna Maria ^a   Lenaz, Giorgio ^a   Romeo, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE;

ARTICLE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MITOCHONDRION; MUTATION; NEOPLASM; OXIDATIVE STRESS; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIA; MUTATION; NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84875126149     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a011411     Document Type: Article

References (121)

1. Acin-Perez R, Bayona-Bafaluy MP, Fernandez-Silva P, Moreno-Loshuertos R, Perez-Martos A, Bruno C, Moraes CT, Enriquez JA. 2004. Respiratory complex III is required to maintain complex I in mammalian mitochondria. Mol Cell 13: 805-815.
2. Ambu R, Riva A, Lai ML, Loffredo F, Riva FT, Tandler B. 2000. Scanning electron microscopy of the interior of cells in Hurthle cell tumors. Ultrastruct Pathol 24: 211-219.
3. Baracca A, Chiaradonna F, Sgarbi G, Solaini G, Alberghina L, Lenaz G. 2010. Mitochondrial complex I de- crease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochim Biophys Acta 1797: 314-323.
4. Baris O, Savagner F, Nasser V, Loriod B, Granjeaud S, Guyetant S, Franc B, Rodien P, Rohmer V, Bertucci F, et al. 2004. Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J Clin Endocrinol Metab 89: 994-1005.
5. Bartoletti-Stella A, Salfi NC, Ceccarelli C, Attimonelli M, Romeo G, Gasparre G. 2011. Mitochondrial DNA mutations in oncocytic adnexal lacrimal glands of the conjunctiva. Arch Ophthalmol 129: 664-666.
6. Bell EL, Klimova T, Chandel NS. 2008. Targeting the mitochondria for cancer therapy: Regulation of hypoxia-inducible factor by mitochondria. Antioxid Redox Signal 10: 635-640.
7. Bianchi C, Fato R, Genova ML, Parenti Castelli G, Lenaz G. 2003. Structural and functional organization of complex I in the mitochondrial respiratory chain. Biofactors 18: 3-9.
8. Blakely EL, Mitchell AL, Fisher N, Meunier B, Nijtmans LG, Schaefer AM, Jackson MJ, Turnbull DM, Taylor RW. 2005. A mitochondrial cytochrome b mutation causing severe respiratory chain enzyme deficiency in humans and yeast. FEBS J 272: 3583-3592.
9. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, Baracca A, Tallini G, Martinuzzi A, Lenaz G, et al. 2006a. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 66: 6087-6096.
10. Bonora E, Evangelisti C, Bonichon F, Tallini G, Romeo G. 2006b. Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. Br J Cancer 4: 1529-1536.
11. Boulahbel H, Duran RV, Gottlieb E. 2009. Prolyl hydroxylases as regulators of cell metabolism. Biochem Soc Trans 37: 291-294.
12. Brahimi-Horn MC, Pouyssegur J. 2007. Oxygen, a source of life and stress. FEBS Lett 581: 3582-3591.
13. Brandon M, Baldi P, Wallace DC. 2006. Mitochondrial mutations in cancer. Oncogene 25: 4647-4662.
14. Butow RA, Avadhani NG. 2004. Mitochondrial signaling: The retrograde response. Mol Cell 14: 1-15.
15. Chen Z, Lu W, Garcia-Prieto C, Huang P. 2007. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39: 267-274.
16. Costa-Guda J, Tokura T, Roth SI, Arnold A. 2007. Mitochondrial DNA mutations in oxyphilic and chief cell parathyroid adenomas. BMC Endocr Disord 7: 8.
17. Cuezva JM, Ortega AD, Willers I, Sanchez-Cenizo L, Aldea M, Sanchez-Arago M. 2009. The tumor suppressor function of mitochondria: Translation into the clinics. Biochim Biophys Acta 1792: 1145-1158.
18. D'Aurelio M, Gajewski CD, Lenaz G, Manfredi G. 2006. Respiratory chain supercomplexes set the threshold for respiration defects in human mtDNA mutant cybrids. Hum Mol Genet 15: 2157-2169.
19. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. 2008. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
20. Diaz F, Fukui H, Garcia S, Moraes CT. 2006. Cytochrome c oxidase is required for the assembly/stability of respira- tory complex I in mouse fibroblasts. Mol Cell Biol 26: 4872-4881.
21. DiMauro S, Hirano M, Schon EA. 2006. Mitochondrial med- icine. Informa Healthcare, London.
22. Finley DJ, Zhu B, Fahey TJ. 2004. Molecular analysis of Hurthle cell neoplasms by gene profiling. Surgery 136: 1160-1168.
23. Frezza C, Gottlieb E. 2009. Mitochondria in cancer: Not just innocent bystanders. Semin Cancer Biol 19: 4-11.
24. Fry M, Green DE. 1980. Cardiolipin requirement by cytochrome oxidase and the catalytic role of phospholipid. Biochem Biophys Res Commun 93: 1238-1246.
25. Fry M, Green DE. 1981. Cardiolipin requirement for electron transfer in complex I and III of the mitochondrial respiratory chain. J Biol Chem 256: 1874-1880.
26. Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, Ghelli A, Moretti M, Betts CM, Martinelli GN, et al. 2007. Disruptive mitochondrial DNA mutationsin complexIsubunits are markers ofoncocytic phenotype in thyroid tumors. Proc Natl Acad Sci 104: 9001-9006.
27. Gasparre G, Hervouet E, de Laplanche E, Demont J, Pennisi LF, Colombel M, Mege-Lechevallier F, Scoazec JY, Bonora E, Smeets R, et al. 2008. Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet 17: 986-995.
28. Gasparre G, Iommarini L, Porcelli AM, Lang M, Ferri GG, Kurelac I, Zuntini R, Mariani E, Pennisi LF, Pasquini E, et al. 2009. An inherited mitochondrial DNA disruptive mutation shifts to homoplasmy in oncocytic tumor cells. Hum Mutat 30: 391-396.
29. Gasparre G, Romeo G, Rugolo M, Porcelli AM. 2011a. Learning from oncocytic tumors: Why choose inefficient mitochondria? Biochim Biophys Acta 1807: 633-642.
30. Gasparre G, Kurelac I, Capristo M, Iommarini L, Ghelli A, Ceccarelli C, Nicoletti G, Nanni P, De Giovanni C, Scotlandi K, et al. 2011b. A mutation threshold distinguishes the anti-tumorigenic effects of the mitochondrial gene MTND1, an oncojanus function. Cancer Res 71: 6220-6229.
31. Genova ML, Baracca A, Biondi A, Casalena G, Faccioli M, Falasca AI, Formiggini G, Sgarbi G, Solaini G, Lenaz G. 2008. Is supercomplex organization of the respiratory chain required for optimal electron transfer activity? Bio- chim Biophys Acta 1777: 740-746.
32. Guerra F, Kurelac I, Cormio A, Zuntini R, Amato LB, Ceccarelli C, Santini D, Cormio G, Fracasso F, Selvaggi L, et al. 2011. Placing mitochondrial DNA mutations with- in the progression model of type I endometrial carcinoma. Hum Mol Genet 20: 2394-2405.
33. Higgins JP, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M, Brooks JD. 2003. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 162: 925-932.
34. Holleran AL, Briscoe DA, Fiskum G, Kelleher JK. 1995. Glutamine metabolism in AS-30D hepatoma cells. Evidence for its conversion into lipids via reductive carboxylation. Mol Cell Biochem 152: 95-101.
35. Ibsen KH. 1961. The Crabtree effect: A review. Cancer Res 21: 829-841.
36. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y, Hayashi J. 2008. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320: 661-664.
37. Jacques C, Baris O, Prunier-Mirebeau D, Savagner F, Rodien P, Rohmer V, Franc B, Guyetant S, Malthiery Y, Reynier P. 2005. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab 90: 2314-2320.
38. Jahnke VE, Sabido O, Defour A, Castells J, Lefai E, Roussel D, Freyssenet D. 2010. Evidence for mitochon- drial respiratory deficiency in rat rhabdomyosarcoma cells. PLoS ONE 5: e8637.
39. Kaluz S, Kaluzova M, Stanbridge EJ. 2008. Rational design of minimal hypoxia-inducible enhancers. Biochem Biophys Res Commun 370: 613-618.
40. Kang SY, Gutowsky HS, Hsung JC, Jacobs R, King TE, Rice D, Oldfield E. 1979. Nuclear magnetic resonance investigation of the cytochrome oxidase-phospholipid interaction: A new model for boundary lipid. Biochemis- try 18: 3257-3267.
41. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. 2006. HIF- 1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185.
42. King A, Selak MA, Gottlieb E. 2006. Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dys- function and cancer. Oncogene 25: 4675-4682.
43. Klaunig JE, Kamendulis LM. 2004. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44: 239-267.
44. Klevecz RR, Bolen J, Forrest G, Murray DB. 2004.Agenome- wide oscillation in transcription gates DNA replication and cell cycle. Proc Natl Acad Sci 101: 1200-1205.
45. Koopman WJ, Verkaart S, Visch HJ, van Emstde Vries S, Nijtmans LG, Smeitink JA, Willems PH. 2007. Human NADH:ubiquinone oxidoreductase deficiency: Radical changes in mitochondrial morphology? Am J Physiol Cell Physiol 293: C22-C29.
46. Koppenol WH, Bounds PL, Dang CV. 2011. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11: 325-337.
47. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR. 1994. Fatty acid synthesis: A potential selective target for antineoplastic therapy. Proc Natl Acad Sci 91: 6379-6383.
48. Kurelac I, Lang M, Zuntini R, Calabrese C, Simone D, Vicario S, Santamaria M, Attimonelli M, Romeo G, Gasparre G. 2011. Searching for a needle in the haystack: Comparing six methods to evaluate heteroplasmy in difficult sequencecontext. Biotechnol Adv 30: 363-371.
49. Lange C, Nett JH, Trumpower BL, Hunte C. 2001. Specific roles of protein-phospholipid interactions in the yeast cytochrome bc1 complex structure. EMBO J 20: 6591-6600.
50. Lee AG. 2004. How lipids affect the activities of integral membrane proteins. Biochim Biophys Acta 1666: 62-87.
51. Lenaz G, Genova ML. 2007. Kinetics of integrated electron transfer in the mitochondrial respiratory chain: Random collisions vs. solid state electron channeling. Am J Physiol Cell Physiol 292: C1221-C1239.
52. Lenaz G, Genova ML. 2010. Structure and organization of mitochondrial respiratory complexes: A new under- standing of an old subject. Antioxid Redox Signal 12: 961-1008.
53. Lenaz G, Strocchi P. 2009. Reactive oxygen species in the induction of toxicity. In General and applied toxicology review (ed. Ballantyne B, et al.), Vol. 2, pp. 367-410. Wiley, Chichester, UK.
54. Lenaz G, Baracca A, Fato R, Genova ML, Solaini G. 2006. New insights into structure and function of mitochon- dria and their role in aging and disease. Antioxid Redox Signal 8: 417-437.
55. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. 2005. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolismtocontrol basal HIF- 1. J Biol Chem 280: 41928-41939.
56. Ma Y, Bai RK, Trieu R, Wong LJ. 2010. Mitochondrial dys- function in human breast cancer cells and their trans- mitochondrial cybrids. Biochim Biophys Acta 1797: 29-37.
57. Mathupala SP, Ko YH, Pedersen PL. 2010. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 1797: 1225-1230.
58. Maximo V, Sobrinho-Simoes M. 2000. Mitochondrial DNA "common" deletion in Hurthle cell lesions of the thyroid. J Pathol 192: 561-562.
59. Maximo V, Sores P, Rocha AS, Sobrinho-Simoes M. 1998. The common deletionof mitochondrial DNA is found in goiters and thyroid tumors with and without oxyphil cell change. Ultrastruct Pathol 22: 271-273.
60. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. 2002. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNAvariants in human thyroid pathology: A study with emphasis on Hurthle cell tumors. Am J Pathol 160: 1857-1865.
61. Maximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR, et al. 2005. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 23: 1892-1898.
62. Maximo V, Lima J, Soares P, Sobrinho-Simoes M. 2009. Mitochondria and cancer. Virchows Arch 454: 481-495.
63. Mayevsky A. 2009. Mitochondrial function and energy metabolism in cancer cells: Past overview and future per- spectives. Mitochondrion 9: 165-179.
64. Mayr JA, Meierhofer D, Zimmermann F, Feichtinger R, Kogler C, Ratschek M, Schmeller N, Sperl W, Kofler B. 2008. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res 14: 2270-2275.
65. McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, Halim ND, Wu H, Schell MJ, Tsang TM, Teahan O, et al. 2008. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 283: 22700-22708.
66. McKenzie M, Lazarou M, Thorburn DR, Ryan MT. 2006. Mitochondrial respiratory chain supercomplexes are de- stabilized in Barth syndrome patients. J Mol Biol 361: 462-469.
67. Moran M, Rivera H, Sanchez-Arago M, Blazquez A, Merinero B, Ugalde C, Arenas J, Cuezva JM, Martin MA. 2010. Mitochondrial bioenergetics and dynamics inter- play in complex I-deficient fibroblasts. Biochim Biophys Acta 1802: 443-453.
68. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E. 2007. Energy metabolismin tumor cells. FEBS J 274: 1393-1418.
69. Morris LG, Veeriah S, Chan TA. 2010. Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene 29: 3453-3464.
70. Muller-Hocker J. 1992. Random cytochrome-c-oxidase deficiency of oxyphil cell nodules in the parathyroid gland. A mitochondrial cytopathy related to cell ageing? Pathol Res Pract 188: 701-706.
71. Muller-Hocker J, Jacob U, Seibel P. 1998a. Hashimoto thyroiditis is associated with defects of cytochrome-c oxidase in oxyphil Askanazy cells and with the common deletion (4,977) of mitochondrial DNA. Ultrastruct Pathol 22: 91-100.
72. Muller-Hocker J, Schafer S, Copeland WC, Wiesner R, Seibel P. 1998b. Immunohistochemical detection of hu- man mtDNA polymeraseg andof human mitochondrial transcription factor A in cytochrome-c-oxidase-deficient oxyphil cells of hyperfunctional parathyroids. Virchows Arch 433: 529-536.
73. Neuwald AF. 1997. Barth syndrome may be due to an acyltransferase deficiency. Curr Biol 7: R465-R466.
74. Ozawa T. 1997. Genetic and functional changes in mitochondria associated with aging. Physiol Rev 77: 425-464.
75. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. 2000. The effect of reactive oxygen species generated from the mitochondrial electron transport chain on the cytochrome c oxidase activity and on the cardiolipin content in bovine heart submitochondrial particles. FEBS Lett 466: 323-326.
76. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. 2002. Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. Gene 286: 135-141.
77. Paradies G, Petrosillo G, Paradies V, Ruggiero FM. 2010. Oxidative stress, mitochondrial bioenergetics, and cardiolipin in aging. Free Radic Biol Med 48: 1286-1295.
78. Park JS, Sharma LK, Li H, Xiang R, Holstein D, Wu J, Lechleiter J, Naylor SL, Deng JJ, Lu J, et al. 2009. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet 18: 1578-1589.
79. Parlo RA, Coleman PS. 1986. Continuous pyruvate carbon flux to newly synthesized cholesterol and the suppressed evolution of pyruvate-generated CO2 in tumors: Further evidence for a persistent truncated Krebs cycle in hepatomas. Biochim Biophys Acta 886: 169-176.
80. Pasini B, Stratakis CA. 2009. SDH mutations in tumorigenesis and inherited endocrine tumours: Lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med 266: 19-42.
81. Patten DA, Lafleur VN, Robitaille GA, Chan DA, Giaccia AJ, Richard DE. 2010. Hypoxia-inducible factor-1 activation in nonhypoxic conditions: The essential role of mitochondrial-derived reactive oxygen species. Mol Biol Cell 21: 3247-3257.
82. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH et al. 2005. MtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci 102: 719-724.
83. Petrosillo G, Ruggiero FM, Di Venosa N, Paradies G. 2003. Decreased complex III activity in mitochondria isolated from rat heart subjected to ischemia and reperfusion: Role of reactive oxygen species and cardiolipin. FASEB J 17: 714-716.
84. Petrosillo G, Matera M, Moro N, Ruggiero FM, Paradies G. 2009. Mitochondrial complex I dysfunction in rat heart with aging: Critical role of reactive oxygen species and cardiolipin. Free Radic Biol Med 46: 88-94.
85. Pfeiffer K, Gohil V, Stuart RA, Hunte C, Brandt U, Greenberg ML, Schagger H. 2003. Cardiolipin stabilizes respiratory chain supercomplexes. J Biol Chem 278: 52873-52880.
86. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Olpin S, Moat SJ, Hargreaves IP, et al. 2005. Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14: 2231-2239.
87. Porcelli AM, Angelin A, Ghelli A, Mariani E, Martinuzzi A, Carelli V, Petronilli V, Bernardi P, Rugolo M. 2009. Respi- ratory complex I dysfunction due to mitochondrial DNA mutations shifts the voltage threshold for opening of the permeability transition pore toward resting levels. J Biol Chem 284: 2045-2052.
88. Porcelli A, Ghelli A, Ceccarelli C, Lang M, Cenacchi G, Capristo M, Pennisi LF, Ciccarelli E, Melcarne A, Bartoletti-Stella A, et al. 2010. The genetic and metabolic signature of oncocytic transformation implicates HIF1a destabilization. Hum Mol Genet 19: 1019-1032.
89. Pradella LM, Zuntini R, Magini P, Ceccarelli C, Neri I, Cerasoli S, Graziano C, Gasparre G, Turchetti D. 2011. Two distinct thyroid tumours in a patient with Cowden syndrome carrying both a 10q23 and a mitochondrial DNA germline deletion. J Med Genet 48: 779-782.
90. Putignani L, Raffa S, Pescosolido R, Aimati L, Signore F, Torrisi MR, Grammatico P. 2008. Alteration of expression levels of the oxidative phosphorylation system (OXPHOS) in breast cancer cell mitochondria. Breast Cancer Res Treat 110: 439-452.
91. Radermacher M, Ruiz T, Clason T, Benjamin S, Brandt U, Zickermann V. 2006. The three-dimensional structure of complex I from Yarrowia lipolytica: A highly dynamic enzyme. J Struct Biol 154: 269-279.
92. Riva A, Tandler B. 2000. Three-dimensional structure of oncocyte mitochondria in human salivary glands: A scanning electron microscope study. Ultrastruct Pathol 24: 145-150.
93. Robinson NC, Strey F, Talbert L. 1980. Investigation of the essential boundary layer phospholipids of cytochrome c oxidase using Triton X-100 delipidation. Biochemistry 19: 3656-3661.
94. Rosca MG, Vazquez EJ, Kerner J, Parland W, Chandler MP, Stanley W, Sabbah HN, Hoppel CL. 2008. Cardiac mitochondria in heart failure: Decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res 80: 30-39.
95. Savagner F, Chevrollier A, Loiseau D, Morgan C, Reynier P, Clark O, Stepien G, Malthiery Y. 2001a. Mitochondrial activity in XTC.UC1 cells derived from thyroid oncocytoma. Thyroid 11: 327-333.
96. Savagner F, Franc B, Guyetant S, Rodien P, Reynier P, Malthiery Y. 2001b. Defective mitochondrial ATP synthe- sis in oxyphilic thyroid tumors. J Clin Endocrinol Metab 86: 4920-4925.
97. Savagner F, Mirebeau D, Jacques C, Guyetant S, Morgan C, Franc B, Reynier P, Malthiery Y. 2003. PGC-1-related co- activator and targets are upregulated in thyroid oncocytoma. Biochem Biophys Res Commun 310: 779-784.
98. Schafer E, Dencher NA, Vonck J, Parcej DN. 2007. Three- dimensional structure of the respiratory chain supercomplex I1III2IV1 from bovine heart mitochondria. Biochemistry 46: 12579-12585.
99. Schagger H, de Coo R, Bauer MF, Hofmann S, Godinot C, Brandt U. 2004. Significance of respirasomes for the assembly/stability of human respiratory chain complex I. J Biol Chem 279: 36349-36353.
100. Sedlak E, Robinson NC. 1999. Phospholipase A(2) digestion of cardiolipin bound to bovine cytochrome c oxidase alters both activity and quaternary structure. Biochemistry 38: 14966-14972.
101. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
102. Semenza GL. 2007. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 405: 1-9.
103. Shidara Y, Yamagata K, Kanamori T, Nakano K, Kwong JQ, Manfredi G, Oda H, Ohta S. 2005. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res 65: 1655-1663.
104. Simonnet H, Demont J, Pfeiffer K, Guenaneche L, Bouvier R, Brandt U, Schagger H, Godinot C. 2003. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis 24: 1461-1466.
105. Smolkova K, Plecita-Hlavata L, Bellance N, Benard G, Rossignol R, Jezek P. 2010. Waves of gene regulation sup- press and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol 43: 950-968.
106. Sun W, Zhou S, Chang SS, McFate T, Verma A, Califano JA. 2009. Mitochondrial mutations contribute to HIF1a accumulation via increased reactive oxygen species and upregulated pyruvate dehydrogenease kinase 2 in head and neck squamous cell carcinoma. Clin Cancer Res 15: 476-484.
107. Tallini G. 1998. Oncocytic tumours. Virchows Arch 433: 5-12.
108. Tallini G, Ladanyi M, Rosai J, Jhanwar SC. 1994. Analysis of nuclear and mitochondrial DNA alterations in thyroid and renal oncocytic tumors. Cytogenet Cell Genet 66: 253-259.
109. Thompson CB. 2009. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 360: 813-815.
110. Tuppen HA, Blakely EL, Worgan L, Al-Dosary M, Saretzki G, Alston CL, Morris AA, Clarke M, Jones S, Devlin AM, et al. 2010. The p.M292T NDUFS2 mutation causes complex I-deficient Leigh syndrome in multiple families. Brain 133: 2952-2963.
111. van Raam BJ, Sluiter W, de Wit E, Roos D, Verhoeven AJ, Kuijpers TW. 2008. Mitochondrial membrane potential in human neutrophils is maintained by complex III activity in the absence of supercomplex organisation. PLoS ONE 3: e2013.
112. Vik SB, Capaldi RA. 1977. Lipid requirements for cytochrome c oxidase activity. Biochemistry 16: 5755-5759.
113. Wallace DC. 2005. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet 39: 359-407.
114. Warburg O. 1956. On the origin of cancer cells. Science 123: 309-314.
115. Weinberg F, Chandel NS. 2009. Mitochondrial metabolism and cancer. Ann NY Acad Sci 1177: 66-73.
116. Yoo H, Antoniewicz MR, Stephanopoulos G, Kelleher JK. 2008. Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipocyte cell line. J Biol Chem 283: 20621-20627.
117. Zhang M, Mileykovskaya E, Dowhan W. 2002. Gluing the respiratory chain together. Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane. J Biol Chem 277: 43553-43556.
118. Zielke A, Tezelman S, Jossart GH, Wong M, Siperstein AE, Duh QY, Clark OH. 1998. Establishment of a highly differentiated thyroid cancer cell line of Hurthle cell origin. Thyroid 8: 475-483.
119. Zimmermann FA, Mayr JA, Neureiter D, Feichtinger R, Alinger B, Jones ND, Eder W, Sperl W, Kofler B. 2009. Lack of complex I is associated with oncocytic thyroid tumours. Br J Cancer 100: 1434-1437.
120. Zimmermann FA, Mayr JA, Feichtinger R, Neureiter D, Lechner R, Koegler C, Ratschek M, Rusmir H, Sargsyan K, Sperl W, et al. 2011. Respiratory chain complex I is a mitochondrial tumor suppressor of oncocytic tumors. Front Biosci 1: 315-325.
121. Zu XL, Guppy M. 2004. Cancer metabolism: Facts, fantasy, and fiction. Biochem Biophys Res Commun 313: 459-465.